Mie

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Asthma3 trials
• COPD2 trials
• Lung cancer2 trials
• Bronchiectasis1 trial
• Chronic rhinosinusitis with nasal polyps1 trial
• Endometrial cancer1 trial
• Ovarian cancer1 trial

Phase

• Phase 38 trials
• Phase 22 trials

Status

• Recruiting6 trials
• Active, not recruiting2 trials
• Completed2 trials

Lead sponsor

• GlaxoSmithKline10 trials

Running trials

• Recruiting

  A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

  NCT07286266· Phase 3· GlaxoSmithKline· Source

  Contact: Eiji Kondo (principal investigator)

• Recruiting

  A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

  NCT07286331· Phase 3· GlaxoSmithKline· Source

  Contact: Eiji Kondo (principal investigator)

• Recruiting

  A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

  NCT07201051· Phase 2· GlaxoSmithKline· Source

  Contact: Osamu Hataji (principal investigator)

• Recruiting

  eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

  NCT07177339· Phase 3· GlaxoSmithKline· Source

  Contact: Osamu Hataji (principal investigator)

• Recruiting

  A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

  NCT07099898· Phase 3· GlaxoSmithKline· Source

  Contact: Osamu Hataji (principal investigator)

• Recruiting

  Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

  NCT06959095· Phase 3· GlaxoSmithKline· Source

  Contact: Masamichi Yoshida (principal investigator)

• Active, not recruiting

  A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

  NCT06748053· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

  NCT06472076· Phase 3· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD2 recruiting
• Bronchiectasis1 recruiting
• Endometrial cancer1 recruiting
• Lung cancer1 recruiting
• Ovarian cancer1 recruiting

Closed trials

• Completed

  Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

  NCT05274750· Phase 3· GlaxoSmithKline· Source

• Completed

  A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

  NCT04718389· Phase 3· GlaxoSmithKline· Source